Summary:
A phase 3 trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.
The trial duration for subject will be approximately 10-15 weeks and each subject will attend a minimum of 6 visits.
If no documented iron intolerance or unresponsiveness subject with have at a 1 month run-in period. If subject is randomized to Group B they may have an additional 2 treatment visits (TV1-TV2) to attend. You will be compensated $50.00 per in office visit.
Qualified Participants Must:
• Have hemoglobin levels less than 10
•
Be willing to have intravenous infusion treatment as well blood samples drawn at every visit.
Qualified Participants May Receive:
Study related medical care by board-certified professionals, medical test and treatment of the condition as well as $50.00 compensation per office visit.